secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-05-27T12:00:25+00:00
Accession:  0001493152-26-025336
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics terminates Wugen license, regains ex vivo rights to HCW9201/9206 at no cost
--------------------------------------------------------------------------------

- Company exercised option to terminate exclusive worldwide license from Wugen for ex vivo rights to HCW9201 and HCW9206; regained rights at no cost.
- Retained nonrefundable upfront license fee including 2.2 million shares of Wugen common stock.
- Recent data in Science Advances suggests HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies.
- Company plans to commercialize the reagents through partners focused on CAR-T and NK-cell therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226025336/0001493152-26-025336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226025336/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer